<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240917223909&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240917223909&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 18 Sep 2024 02:39:10 +0000</lastbuilddate>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39287435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae631. doi: 10.1093/eurheartj/ehae631. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39287435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39287435</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae631>10.1093/eurheartj/ehae631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39287435</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</dc:title>
<dc:identifier>pmid:39287435</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae631</dc:identifier>
</item>
<item>
<title>Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39286890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17. doi: 10.1161/CIRCULATIONAHA.124.068610. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Oof patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes/(s·cm<sup>-5</sup>). During an observation period (>;3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention (<i>P</i>&lt;0.001). In Kaplan-Meier analysis, 3-year survival was 94%, 92%, and 71% in the 3 groups, respectively. PEA 3-year survival improved by 5% from that observed between 2007 and 2012. There was no survival difference in patients receiving vitamin K antagonists and non-vitamin K oral anticoagulants (<i>P</i>=0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL https://clinicaltrials.gov; Unique identifier: NCT02656238.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39286890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39286890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068610>10.1161/CIRCULATIONAHA.124.068610</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39286890</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marion Delcroix</dc:creator>
<dc:creator>Joanna Pepke-Zaba</dc:creator>
<dc:creator>Andrea M D'Armini</dc:creator>
<dc:creator>Elie Fadel</dc:creator>
<dc:creator>Stefan Guth</dc:creator>
<dc:creator>Stephen P Hoole</dc:creator>
<dc:creator>David P Jenkins</dc:creator>
<dc:creator>David G Kiely</dc:creator>
<dc:creator>Nick H Kim</dc:creator>
<dc:creator>Michael M Madani</dc:creator>
<dc:creator>Hiromi Matsubara</dc:creator>
<dc:creator>Kazuhiko Nakayama</dc:creator>
<dc:creator>Aiko Ogawa</dc:creator>
<dc:creator>Jaquelina S Ota-Arakaki</dc:creator>
<dc:creator>Rozenn Quarck</dc:creator>
<dc:creator>Roela Sadushi-Kolici</dc:creator>
<dc:creator>Gérald Simonneau</dc:creator>
<dc:creator>Christoph B Wiedenroth</dc:creator>
<dc:creator>Bedrettin Yildizeli</dc:creator>
<dc:creator>Eckhard Mayer</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy</dc:title>
<dc:identifier>pmid:39286890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068610</dc:identifier>
</item>
<item>
<title>Differential roles of eosinophils in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39285242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 16. doi: 10.1038/s41569-024-01071-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39285242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39285242</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01071-5>10.1038/s41569-024-01071-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39285242</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Junyan Xu</dc:creator>
<dc:creator>Junli Guo</dc:creator>
<dc:creator>Tianxiao Liu</dc:creator>
<dc:creator>Chongzhe Yang</dc:creator>
<dc:creator>Zhaojie Meng</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Jinying Zhang</dc:creator>
<dc:creator>Guo-Ping Shi</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Differential roles of eosinophils in cardiovascular disease</dc:title>
<dc:identifier>pmid:39285242</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01071-5</dc:identifier>
</item>
<item>
<title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):e267. doi: 10.1161/CIR.0000000000001284. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283938</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001284>10.1161/CIR.0000000000001284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283938</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39283938</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001284</dc:identifier>
</item>
<item>
<title>Artificial Intelligence and Mitral Regurgitation: Friend or Foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):934-937. doi: 10.1161/CIRCULATIONAHA.124.070954. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283937</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070954>10.1161/CIRCULATIONAHA.124.070954</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283937</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Umidakhon Mahkmudova</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Artificial Intelligence and Mitral Regurgitation: Friend or Foe?</dc:title>
<dc:identifier>pmid:39283937</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070954</dc:identifier>
</item>
<item>
<title>Correction to: Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283936/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):e268. doi: 10.1161/CIR.0000000000001286. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283936/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283936</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001286>10.1161/CIR.0000000000001286</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283936</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</dc:title>
<dc:identifier>pmid:39283936</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001286</dc:identifier>
</item>
<item>
<title>Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):e255-e256. doi: 10.1161/CIRCULATIONAHA.123.068415. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283935</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068415>10.1161/CIRCULATIONAHA.123.068415</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283935</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Ethan J Rowin</dc:creator>
<dc:creator>Barry J Maron</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"</dc:title>
<dc:identifier>pmid:39283935</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068415</dc:identifier>
</item>
<item>
<title>Arterial Thrombosis: Present and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):905-907. doi: 10.1161/CIRCULATIONAHA.124.070541. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283934</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070541>10.1161/CIRCULATIONAHA.124.070541</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283934</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arterial Thrombosis: Present and Future</dc:title>
<dc:identifier>pmid:39283934</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070541</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):966-970. doi: 10.1161/CIRCULATIONAHA.124.071870. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283933</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071870>10.1161/CIRCULATIONAHA.124.071870</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283933</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39283933</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071870</dc:identifier>
</item>
<item>
<title>Microplastics and Cardiovascular Diseases: Importance of Coexisting Environmental Pollutants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):908-910. doi: 10.1161/CIRCULATIONAHA.124.069801. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283932</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069801>10.1161/CIRCULATIONAHA.124.069801</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283932</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Duk-Hee Lee</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microplastics and Cardiovascular Diseases: Importance of Coexisting Environmental Pollutants</dc:title>
<dc:identifier>pmid:39283932</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069801</dc:identifier>
</item>
<item>
<title>&lt;em>;LMNA&lt;/em>; Q353R Mutation Causes Dilated Cardiomyopathy Through Impaired Vitamin D Signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):971-974. doi: 10.1161/CIRCULATIONAHA.124.069972. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069972>10.1161/CIRCULATIONAHA.124.069972</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283931</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Masamichi Ito</dc:creator>
<dc:creator>Manami Katoh</dc:creator>
<dc:creator>Tatsuro Sassa</dc:creator>
<dc:creator>Toshiyuki Ko</dc:creator>
<dc:creator>Kanna Fujita</dc:creator>
<dc:creator>Shintaro Yamada</dc:creator>
<dc:creator>Koichiro Miura</dc:creator>
<dc:creator>Masashi Toyoda</dc:creator>
<dc:creator>Shuji Takada</dc:creator>
<dc:creator>Takashige Tobita</dc:creator>
<dc:creator>Mikako Katagiri</dc:creator>
<dc:creator>Masayuki Kubota</dc:creator>
<dc:creator>Takanobu Yamada</dc:creator>
<dc:creator>Satoshi Hatsuse</dc:creator>
<dc:creator>Hiroyuki Morita</dc:creator>
<dc:creator>Masashi Ikeuchi</dc:creator>
<dc:creator>Katsuhisa Matsuura</dc:creator>
<dc:creator>Akihiro Umezawa</dc:creator>
<dc:creator>Seitaro Nomura</dc:creator>
<dc:creator>Hiroyuki Aburatani</dc:creator>
<dc:creator>Issei Komuro</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;LMNA&lt;/em>; Q353R Mutation Causes Dilated Cardiomyopathy Through Impaired Vitamin D Signaling</dc:title>
<dc:identifier>pmid:39283931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069972</dc:identifier>
</item>
<item>
<title>Response from Harmon et al to Letter Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):e257-e258. doi: 10.1161/CIRCULATIONAHA.124.070246. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283930</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070246>10.1161/CIRCULATIONAHA.124.070246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283930</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:creator>Timothy W Churchhill</dc:creator>
<dc:creator>Nathaniel Moulsen</dc:creator>
<dc:creator>Stephanie A Kliethermes</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Jonathan A Drezner</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>David M Siebert</dc:creator>
<dc:creator>Lauren Salerno</dc:creator>
<dc:creator>Monica Zigman Suchsland</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Bradley J Petek</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response from Harmon et al to Letter Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"</dc:title>
<dc:identifier>pmid:39283930</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070246</dc:identifier>
</item>
<item>
<title>Expanding Opportunities by Adding Accessibility to Diversity, Equity, and Inclusion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):903-904. doi: 10.1161/CIRCULATIONAHA.124.071728. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39283929</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071728>10.1161/CIRCULATIONAHA.124.071728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283929</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Walter K Clair</dc:creator>
<dc:creator>Anne E Sumner</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>AHA Journals DEIA Editorial Board</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Expanding Opportunities by Adding Accessibility to Diversity, Equity, and Inclusion</dc:title>
<dc:identifier>pmid:39283929</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071728</dc:identifier>
</item>
<item>
<title>Chronic Activation of Tubulin Tyrosination Improves Heart Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39279670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides the first proof of concept that chronic activation of tubulin tyrosination in HCM mice and in human EHTs improves heart function and holds promise for targeting the nonsarcomeric cytoskeleton in heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 16. doi: 10.1161/CIRCRESAHA.124.324387. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RATIONALE: Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disorder caused by sarcomeric gene variants and associated with left ventricular hypertrophy and diastolic dysfunction. The role of the microtubule network has recently gained interest with the findings that microtubule detyrosination (dTyr-MT) is markedly elevated in heart failure. Acute reduction of dTyr-MT by inhibition of the detyrosinase (VASH [vasohibin]/SVBP [small VASH-binding protein] complex) or activation of the tyrosinase (TTL [tubulin tyrosine ligase]) markedly improved contractility and reduced stiffness in human failing cardiomyocytes and thus posed a new perspective for HCM treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: In this study, we tested the impact of chronic tubulin tyrosination in an HCM mouse model (<i>Mybpc3</i> knock in), in human HCM cardiomyocytes, and in SVBP-deficient human engineered heart tissues (EHTs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Adeno-associated virus serotype 9-mediated TTL transfer was applied in neonatal wild-type rodents, in 3-week-old knock-in mice, and in HCM human induced pluripotent stem cell-derived cardiomyocytes. We show (1) TTL for 6 weeks dose dependently reduced dTyr-MT and improved contractility without affecting cytosolic calcium transients in wild-type cardiomyocytes; (2) TTL for 12 weeks reduced the abundance of dTyr-MT in the myocardium, improved diastolic filling, compliance, cardiac output, and stroke volume in knock-in mice; (3) TTL for 10 days normalized cell area in HCM human induced pluripotent stem cell-derived cardiomyocytes; (4) TTL overexpression activated transcription of tubulins and other cytoskeleton components but did not significantly impact the proteome in knock-in mice; (5) SVBP-deficient EHTs exhibited reduced dTyr-MT levels, higher force, and faster relaxation than TTL-deficient and wild-type EHTs. RNA sequencing and mass spectrometry analysis revealed distinct enrichment of cardiomyocyte components and pathways in SVBP-deficient versus TTL-deficient EHTs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides the first proof of concept that chronic activation of tubulin tyrosination in HCM mice and in human EHTs improves heart function and holds promise for targeting the nonsarcomeric cytoskeleton in heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39279670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39279670</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324387>10.1161/CIRCRESAHA.124.324387</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39279670</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Niels Pietsch</dc:creator>
<dc:creator>Christina Y Chen</dc:creator>
<dc:creator>Svenja Kupsch</dc:creator>
<dc:creator>Lucas Bacmeister</dc:creator>
<dc:creator>Birgit Geertz</dc:creator>
<dc:creator>Marisol Herrera-Rivero</dc:creator>
<dc:creator>Bente Siebels</dc:creator>
<dc:creator>Hanna Voß</dc:creator>
<dc:creator>Elisabeth Krämer</dc:creator>
<dc:creator>Ingke Braren</dc:creator>
<dc:creator>Dirk Westermann</dc:creator>
<dc:creator>Hartmut Schlüter</dc:creator>
<dc:creator>Giulia Mearini</dc:creator>
<dc:creator>Saskia Schlossarek</dc:creator>
<dc:creator>Jolanda van der Velden</dc:creator>
<dc:creator>Matthew Caporizzo</dc:creator>
<dc:creator>Diana Lindner</dc:creator>
<dc:creator>Benjamin L Prosser</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Chronic Activation of Tubulin Tyrosination Improves Heart Function</dc:title>
<dc:identifier>pmid:39279670</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324387</dc:identifier>
</item>
<item>
<title>Social Determinants of Cardiovascular Health in Asian Americans: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39279648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>To achieve cardiovascular health (CVH) equity in the United States, an understanding of the social and structural factors that contribute to differences and disparities in health is necessary. The Asian American population is the fastest-growing racial group in the United States but remains persistently underrepresented in health research. There is heterogeneity in how individual Asian American ethnic groups experience CVH and cardiovascular disease outcomes, with certain ethnic groups...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 16. doi: 10.1161/CIR.0000000000001278. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">To achieve cardiovascular health (CVH) equity in the United States, an understanding of the social and structural factors that contribute to differences and disparities in health is necessary. The Asian American population is the fastest-growing racial group in the United States but remains persistently underrepresented in health research. There is heterogeneity in how individual Asian American ethnic groups experience CVH and cardiovascular disease outcomes, with certain ethnic groups experiencing a higher burden of adverse social conditions, disproportionately high burden of suboptimal CVH, or excess adverse cardiovascular disease outcomes. In this scientific statement, upstream structural and social determinants that influence CVH in the Asian American population are highlighted, with particular emphasis on the role of social determinants of health across disaggregated Asian American ethnic groups. Key social determinants that operate in Asian American communities include socioeconomic position, immigration and nativity, social and physical environments, food and nutrition access, and health system-level factors. The role of underlying structural factors such as health, social, and economic policies and structural racism is also discussed in the context of CVH in Asian Americans. To improve individual-, community-, and population-level CVH and to reduce CVH disparities in Asian American ethnic subgroups, multilevel interventions that address adverse structural and social determinants are critical to achieve CVH equity for the Asian American population. Critical research gaps for the Asian American population are given, along with recommendations for strategic approaches to investigate social determinants of health and intervene to reduce health disparities in these communities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39279648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39279648</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001278>10.1161/CIR.0000000000001278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39279648</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Namratha R Kandula</dc:creator>
<dc:creator>Yvonne Commodore-Mensah</dc:creator>
<dc:creator>Brittany N Morey</dc:creator>
<dc:creator>Shivani A Patel</dc:creator>
<dc:creator>Sally Wong</dc:creator>
<dc:creator>Eugene Yang</dc:creator>
<dc:creator>Stella Yi</dc:creator>
<dc:creator>American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Lifestyle and Cardiometabolic Health; Council on Basic Cardiovascular Sciences; Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Social Determinants of Cardiovascular Health in Asian Americans: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39279648</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001278</dc:identifier>
</item>
<item>
<title>Great debate: myocardial infarction after cardiac surgery must be redefined</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39279125/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 16:ehae416. doi: 10.1093/eurheartj/ehae416. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39279125/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39279125</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae416>10.1093/eurheartj/ehae416</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39279125</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:creator>Milan Milojevic</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Philip J Deveraux</dc:creator>
<dc:creator>Kristian Thygesen</dc:creator>
<dc:creator>Patrick O Myers</dc:creator>
<dc:creator>Jolanda Kluin</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Great debate: myocardial infarction after cardiac surgery must be redefined</dc:title>
<dc:identifier>pmid:39279125</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae416</dc:identifier>
</item>
<item>
<title>Long-term mesoscale imaging of 3D intercellular dynamics across a mammalian organ</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>A comprehensive understanding of physio-pathological processes necessitates non-invasive intravital three-dimensional (3D) imaging over varying spatial and temporal scales. However, huge data throughput, optical heterogeneity, surface irregularity, and phototoxicity pose great challenges, leading to an inevitable trade-off between volume size, resolution, speed, sample health, and system complexity. Here, we introduce a compact real-time, ultra-large-scale, high-resolution 3D mesoscope (RUSH3D),...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 11:S0092-8674(24)00917-6. doi: 10.1016/j.cell.2024.08.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A comprehensive understanding of physio-pathological processes necessitates non-invasive intravital three-dimensional (3D) imaging over varying spatial and temporal scales. However, huge data throughput, optical heterogeneity, surface irregularity, and phototoxicity pose great challenges, leading to an inevitable trade-off between volume size, resolution, speed, sample health, and system complexity. Here, we introduce a compact real-time, ultra-large-scale, high-resolution 3D mesoscope (RUSH3D), achieving uniform resolutions of 2.6 × 2.6 × 6 μm<sup>3</sup> across a volume of 8,000 × 6,000 × 400 μm<sup>3</sup> at 20 Hz with low phototoxicity. Through the integration of multiple computational imaging techniques, RUSH3D facilitates a 13-fold improvement in data throughput and an orders-of-magnitude reduction in system size and cost. With these advantages, we observed premovement neural activity and cross-day visual representational drift across the mouse cortex, the formation and progression of multiple germinal centers in mouse inguinal lymph nodes, and heterogeneous immune responses following traumatic brain injury-all at single-cell resolution, opening up a horizon for intravital mesoscale study of large-scale intercellular interactions at the organ level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39276776</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.026>10.1016/j.cell.2024.08.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276776</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuanlong Zhang</dc:creator>
<dc:creator>Mingrui Wang</dc:creator>
<dc:creator>Qiyu Zhu</dc:creator>
<dc:creator>Yuduo Guo</dc:creator>
<dc:creator>Bo Liu</dc:creator>
<dc:creator>Jiamin Li</dc:creator>
<dc:creator>Xiao Yao</dc:creator>
<dc:creator>Chui Kong</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Yuchao Huang</dc:creator>
<dc:creator>Hai Qi</dc:creator>
<dc:creator>Jiamin Wu</dc:creator>
<dc:creator>Zengcai V Guo</dc:creator>
<dc:creator>Qionghai Dai</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Long-term mesoscale imaging of 3D intercellular dynamics across a mammalian organ</dc:title>
<dc:identifier>pmid:39276776</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.026</dc:identifier>
</item>
<item>
<title>Neoself-antigens are the primary target for autoreactive T cells in human lupus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>Major histocompatibility complex class II (MHC-II) is the most significant genetic risk factor for systemic lupus erythematosus (SLE), but the nature of the self-antigens that trigger autoimmunity remains unclear. Unusual self-antigens, termed neoself-antigens, are presented on MHC-II in the absence of the invariant chain essential for peptide presentation. Here, we demonstrate that neoself-antigens are the primary target for autoreactive T cells clonally expanded in SLE. When neoself-antigen...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 11:S0092-8674(24)00913-9. doi: 10.1016/j.cell.2024.08.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Major histocompatibility complex class II (MHC-II) is the most significant genetic risk factor for systemic lupus erythematosus (SLE), but the nature of the self-antigens that trigger autoimmunity remains unclear. Unusual self-antigens, termed neoself-antigens, are presented on MHC-II in the absence of the invariant chain essential for peptide presentation. Here, we demonstrate that neoself-antigens are the primary target for autoreactive T cells clonally expanded in SLE. When neoself-antigen presentation was induced by deleting the invariant chain in adult mice, neoself-reactive T cells were clonally expanded, leading to the development of lupus-like disease. Furthermore, we found that neoself-reactive CD4<sup>+</sup> T cells were significantly expanded in SLE patients. A high frequency of Epstein-Barr virus reactivation is a risk factor for SLE. Neoself-reactive lupus T cells were activated by Epstein-Barr-virus-reactivated cells through downregulation of the invariant chain. Together, our findings imply that neoself-antigen presentation by MHC-II plays a crucial role in the pathogenesis of SLE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39276775</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.025>10.1016/j.cell.2024.08.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276775</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shunsuke Mori</dc:creator>
<dc:creator>Masako Kohyama</dc:creator>
<dc:creator>Yoshiaki Yasumizu</dc:creator>
<dc:creator>Asa Tada</dc:creator>
<dc:creator>Kaito Tanzawa</dc:creator>
<dc:creator>Tatsuya Shishido</dc:creator>
<dc:creator>Kazuki Kishida</dc:creator>
<dc:creator>Hui Jin</dc:creator>
<dc:creator>Masayuki Nishide</dc:creator>
<dc:creator>Shoji Kawada</dc:creator>
<dc:creator>Daisuke Motooka</dc:creator>
<dc:creator>Daisuke Okuzaki</dc:creator>
<dc:creator>Ryota Naito</dc:creator>
<dc:creator>Wataru Nakai</dc:creator>
<dc:creator>Teru Kanda</dc:creator>
<dc:creator>Takayuki Murata</dc:creator>
<dc:creator>Chikashi Terao</dc:creator>
<dc:creator>Koichiro Ohmura</dc:creator>
<dc:creator>Noriko Arase</dc:creator>
<dc:creator>Tomohiro Kurosaki</dc:creator>
<dc:creator>Manabu Fujimoto</dc:creator>
<dc:creator>Tadahiro Suenaga</dc:creator>
<dc:creator>Atsushi Kumanogoh</dc:creator>
<dc:creator>Shimon Sakaguchi</dc:creator>
<dc:creator>Yoshihiro Ogawa</dc:creator>
<dc:creator>Hisashi Arase</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neoself-antigens are the primary target for autoreactive T cells in human lupus</dc:title>
<dc:identifier>pmid:39276775</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.025</dc:identifier>
</item>
<item>
<title>Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8^(+) T cells. Optimal mitochondrial transfer required Talin 2 on both donor...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 12:S0092-8674(24)00956-5. doi: 10.1016/j.cell.2024.08.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8<sup>+</sup> T cells. Optimal mitochondrial transfer required Talin 2 on both donor and recipient cells. CD8<sup>+</sup> T cells with donated mitochondria displayed enhanced mitochondrial respiration and spare respiratory capacity. When transferred into tumor-bearing hosts, these supercharged T cells expanded more robustly, infiltrated the tumor more efficiently, and exhibited fewer signs of exhaustion compared with T cells that did not take up mitochondria. As a result, mitochondria-boosted CD8<sup>+</sup> T cells mediated superior antitumor responses, prolonging animal survival. These findings establish intercellular mitochondrial transfer as a prototype of organelle medicine, opening avenues to next-generation cell therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39276774</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.029>10.1016/j.cell.2024.08.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276774</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeremy G Baldwin</dc:creator>
<dc:creator>Christoph Heuser-Loy</dc:creator>
<dc:creator>Tanmoy Saha</dc:creator>
<dc:creator>Roland C Schelker</dc:creator>
<dc:creator>Dragana Slavkovic-Lukic</dc:creator>
<dc:creator>Nicholas Strieder</dc:creator>
<dc:creator>Inmaculada Hernandez-Lopez</dc:creator>
<dc:creator>Nisha Rana</dc:creator>
<dc:creator>Markus Barden</dc:creator>
<dc:creator>Fabio Mastrogiovanni</dc:creator>
<dc:creator>Azucena Martín-Santos</dc:creator>
<dc:creator>Andrea Raimondi</dc:creator>
<dc:creator>Philip Brohawn</dc:creator>
<dc:creator>Brandon W Higgs</dc:creator>
<dc:creator>Claudia Gebhard</dc:creator>
<dc:creator>Veena Kapoor</dc:creator>
<dc:creator>William G Telford</dc:creator>
<dc:creator>Sanjivan Gautam</dc:creator>
<dc:creator>Maria Xydia</dc:creator>
<dc:creator>Philipp Beckhove</dc:creator>
<dc:creator>Sina Frischholz</dc:creator>
<dc:creator>Kilian Schober</dc:creator>
<dc:creator>Zacharias Kontarakis</dc:creator>
<dc:creator>Jacob E Corn</dc:creator>
<dc:creator>Matteo Iannacone</dc:creator>
<dc:creator>Donato Inverso</dc:creator>
<dc:creator>Michael Rehli</dc:creator>
<dc:creator>Jessica Fioravanti</dc:creator>
<dc:creator>Shiladitya Sengupta</dc:creator>
<dc:creator>Luca Gattinoni</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy</dc:title>
<dc:identifier>pmid:39276774</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.029</dc:identifier>
</item>
<item>
<title>A developmental gradient reveals biosynthetic pathways to eukaryotic toxins in monocot geophytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>Numerous eukaryotic toxins that accumulate in geophytic plants are valuable in the clinic, yet their biosynthetic pathways have remained elusive. A notable example is the >;150 Amaryllidaceae alkaloids (AmAs), including galantamine, an FDA-approved treatment for Alzheimer's disease. We show that while AmAs accumulate to high levels in many daffodil tissues, biosynthesis is localized to nascent, growing tissue at the leaf base. A similar trend is found in the production of steroidal alkaloids...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 10:S0092-8674(24)00918-8. doi: 10.1016/j.cell.2024.08.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Numerous eukaryotic toxins that accumulate in geophytic plants are valuable in the clinic, yet their biosynthetic pathways have remained elusive. A notable example is the >;150 Amaryllidaceae alkaloids (AmAs), including galantamine, an FDA-approved treatment for Alzheimer's disease. We show that while AmAs accumulate to high levels in many daffodil tissues, biosynthesis is localized to nascent, growing tissue at the leaf base. A similar trend is found in the production of steroidal alkaloids (e.g., cyclopamine) in corn lily. This model of active biosynthesis enabled the elucidation of a complete set of biosynthetic genes that can be used to produce AmAs. Taken together, our work sheds light on the developmental and enzymatic logic of diverse alkaloid biosynthesis in daffodils. More broadly, it suggests a paradigm for biosynthesis regulation in monocot geophytes, where plants are protected from herbivory through active charging of newly formed cells with eukaryotic toxins that persist as above-ground tissue develops.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39276773</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.027>10.1016/j.cell.2024.08.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276773</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Niraj Mehta</dc:creator>
<dc:creator>Yifan Meng</dc:creator>
<dc:creator>Richard Zare</dc:creator>
<dc:creator>Rina Kamenetsky-Goldstein</dc:creator>
<dc:creator>Elizabeth Sattely</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A developmental gradient reveals biosynthetic pathways to eukaryotic toxins in monocot geophytes</dc:title>
<dc:identifier>pmid:39276773</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.027</dc:identifier>
</item>
<item>
<title>Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240917223909&amp;v=2.18.0.post9+e462414
      <description>Protein aggregation causes a wide range of neurodegenerative diseases. Targeting and removing aggregates, but not the functional protein, is a considerable therapeutic challenge. Here, we describe a therapeutic strategy called "RING-Bait," which employs an aggregating protein sequence combined with an E3 ubiquitin ligase. RING-Bait is recruited into aggregates, whereupon clustering dimerizes the RING domain and activates its E3 function, resulting in the degradation of the aggregate complex. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 10:S0092-8674(24)00912-7. doi: 10.1016/j.cell.2024.08.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Protein aggregation causes a wide range of neurodegenerative diseases. Targeting and removing aggregates, but not the functional protein, is a considerable therapeutic challenge. Here, we describe a therapeutic strategy called "RING-Bait," which employs an aggregating protein sequence combined with an E3 ubiquitin ligase. RING-Bait is recruited into aggregates, whereupon clustering dimerizes the RING domain and activates its E3 function, resulting in the degradation of the aggregate complex. We exemplify this concept by demonstrating the specific degradation of tau aggregates while sparing soluble tau. Unlike immunotherapy, RING-Bait is effective against both seeded and cell-autonomous aggregation. RING-Bait removed tau aggregates seeded from Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) brain extracts and was also effective in primary neurons. We used a brain-penetrant adeno-associated virus (AAV) to treat P301S tau transgenic mice, reducing tau pathology and improving motor function. A RING-Bait strategy could be applied to other neurodegenerative proteinopathies by replacing the Bait sequence to match the target aggregate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240917223909&v=2.18.0.post9+e462414">39276772</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.024>10.1016/j.cell.2024.08.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276772</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Lauren V C Miller</dc:creator>
<dc:creator>Guido Papa</dc:creator>
<dc:creator>Marina Vaysburd</dc:creator>
<dc:creator>Shi Cheng</dc:creator>
<dc:creator>Paul W Sweeney</dc:creator>
<dc:creator>Annabel Smith</dc:creator>
<dc:creator>Catarina Franco</dc:creator>
<dc:creator>Taxiarchis Katsinelos</dc:creator>
<dc:creator>Melissa Huang</dc:creator>
<dc:creator>Sophie A I Sanford</dc:creator>
<dc:creator>Jonathan Benn</dc:creator>
<dc:creator>Jasmine Farnsworth</dc:creator>
<dc:creator>Katie Higginson</dc:creator>
<dc:creator>Holly Joyner</dc:creator>
<dc:creator>William A McEwan</dc:creator>
<dc:creator>Leo C James</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function</dc:title>
<dc:identifier>pmid:39276772</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.024</dc:identifier>
</item>





























</channel>
</rss>